

Press Release



Partnership Agreement between Yabu City, Hyogo, and Shionogi on the Improvement of Community Healthcare

HYOGO and OSAKA, Japan, March 10, 2020 - Yabu City, Hyogo (Mayor: Sakae Hirose; hereafter, “Yabu City”) and Shionogi & Co.,Ltd. (Head office: Osaka; President and CEO: Isao Teshirogi,Ph.D.; hereafter, “Shionogi”) have entered into a partnership agreement on the improvement of community healthcare (hereafter, the “Agreement”) as below.

Under the Agreement, Yabu City and Shionogi will leverage their respective strengths in close coordination with each other to carry out the following initiatives:

(1) Matters concerning healthcare accessibility of local residents

Partnership for proposing deregulation in the healthcare field by Yabu City, a national strategic special zone

(2) Matters concerning the prevention of infectious diseases and their spread

Holding educational seminars on the prevention of infectious diseases, etc.

(3) Other matters concerning health maintenance of local residents

Plans for new projects through continuous discussions between the two parties

Since being designated as a national strategic special zone in May 2014 to solve the various issues of mountainous areas, which are said to account for around 70% of Japan’s land area, Yabu City has been engaged in a wide range of deregulatory initiatives, such as in the agriculture, healthcare, and public transport areas. Among such initiatives, through the “Special Provisions for Medication Instructions via Videophone” in the healthcare field, Yabu City aims to propose and realize “online treatment of influenza completed within the home” as a new deregulation menu of the national strategic special zone so that an integrated operation of treatment and medication instructions using videophone would be an option against influenza virus infections, since a remote environment, which is the principal characteristic of videophone, is effective in preventing the spread of infectious diseases and it has become relatively easy to use influenza diagnosis kits, whose diagnosis accuracy is sufficiently high.

In its medium-term business plan “SGS2020,” which set forth its management vision to grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare, Shionogi identifies “protecting people from the threat of infectious diseases” as one of its core social missions. To that end, Shionogi has been engaged in R&D of infectious disease drugs necessary to protect the health of the people and promoting proper use of anti-infective drugs. In April 2016 it established the Biomarker R&D Department to develop diagnostic agents and prognostic control methods. Furthermore, since the dissemination of the right knowledge in preventing infection and infectious diseases is essential to promote proper use of anti-infective drugs, Shionogi is actively making efforts in educational activities toward the general public and healthcare workers.

The need for action on social issues to achieve a sustainable world has been increasing every year.

Accordingly, the Sustainable Development Goals (SDGs) were adopted at a UN Summit as international targets to be met by 2030. We are being called on to contribute to these goals as members of society. Based on the Agreement, Yabu City and Shionogi will bring together their respective strengths to solve the challenges that face communities with limited medical resources, such as mountainous areas and remote islands and places, as well as make efforts to improve community healthcare by realizing the special zone proposal and enhancing health and hygiene measures.



SDGs : Goals that apply to this theme

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

Yabu city
Telephone: +81-7-9662-3167
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885